Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.

IF 5.5 3区医学 Q1 IMMUNOLOGY Expert Review of Vaccines Pub Date : 2024-01-01 Epub Date: 2024-03-01 DOI:10.1080/14760584.2024.2322543

Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena

{"title":"Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.","authors":"Cody Palmer, Christiaan Dolk, Ugne Sabale, Wei Wang, Kunal Saxena","doi":"10.1080/14760584.2024.2322543","DOIUrl":null,"url":null,"abstract":"Background: A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.Research design and methods: We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 years using a validated deterministic dynamic transmission metapopulation model.Results: Compared to 2vHPV, the 9vHPV strategy averted an additional 3,245 cases of and 825 deaths from 9vHPV-strain-attributable cancers, 4,247 cases of and 190 deaths from recurrent respiratory papillomatosis (RRP), and 1,009,637 cases of anogenital warts (AGWs), with an incremental cost-effectiveness ratio (ICER) of €4,975 per quality-adjusted life year (QALY) gained. The ICER increased in a scenario with increased HPV vaccination coverage rates and was relatively robust to one-way deterministic sensitivity analyses, with variation in the disease utility parameter having the most impact. When catch-up vaccination for individuals ≤26 years of age was added to the model, vaccinating with 9vHPV averted additional cancers and AGWs compared to 2vHPV vaccination.Conclusion: Our analyses predict that transitioning from a 2vHPV- to a 9vHPV-based vaccination strategy would be cost-effective in the Netherlands.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"312-323"},"PeriodicalIF":5.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2322543","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A bivalent human papillomavirus vaccine (2vHPV) is currently used in the Netherlands; a nonavalent vaccine (9vHPV) is also licensed.

Research design and methods: We compared the public health and economic benefits of 2vHPV- and 9vHPV-based vaccination strategies in the Netherlands over 100 years using a validated deterministic dynamic transmission metapopulation model.

Results: Compared to 2vHPV, the 9vHPV strategy averted an additional 3,245 cases of and 825 deaths from 9vHPV-strain-attributable cancers, 4,247 cases of and 190 deaths from recurrent respiratory papillomatosis (RRP), and 1,009,637 cases of anogenital warts (AGWs), with an incremental cost-effectiveness ratio (ICER) of €4,975 per quality-adjusted life year (QALY) gained. The ICER increased in a scenario with increased HPV vaccination coverage rates and was relatively robust to one-way deterministic sensitivity analyses, with variation in the disease utility parameter having the most impact. When catch-up vaccination for individuals ≤26 years of age was added to the model, vaccinating with 9vHPV averted additional cancers and AGWs compared to 2vHPV vaccination.

Conclusion: Our analyses predict that transitioning from a 2vHPV- to a 9vHPV-based vaccination strategy would be cost-effective in the Netherlands.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

荷兰无空洞 HPV 疫苗接种的成本效益。

背景：荷兰目前使用的是二价人类乳头瘤病毒疫苗（2vHPV）；无价疫苗（9vHPV）也已获得许可：研究设计：我们使用一个经过验证的确定性动态传播元种群模型，比较了荷兰在 100 年内基于 2vHPV 和 9vHPV 疫苗接种策略的公共卫生和经济效益：与 2vHPV 相比，9vHPV 疫苗接种策略避免了额外的 3,245 例 9vHPV 株相关癌症病例和 825 例死亡病例、4,247 例复发性呼吸道乳头状瘤病 (RRP) 病例和 190 例死亡病例，以及 1,009,637 例生殖器疣 (AGW)病例，每获得质量调整生命年 (QALY) 的增量成本效益比 (ICER) 为 4,975 欧元。在 HPV 疫苗接种覆盖率增加的情况下，ICER 会增加，并且对单向确定性敏感性分析相对稳健，疾病效用参数的变化影响最大。如果将≤26岁人群的补种疫苗加入模型，与接种2vHPV疫苗相比，接种9vHPV疫苗可避免更多癌症和AGW：我们的分析预测，在荷兰，从 2vHPV 过渡到 9vHPV 将是一项具有成本效益的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.